Clinical Trial Update: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating exenatide as monotherapy and adjunctive therapy for adolescents with type 2 diabetes completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2020-12-01